Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma-Reference-Cited by-同舟云学术

Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma

Published:2020-04-20 Issue:4 Volume:15 Page:e0231828
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Kirino Sakura,Tsuchiya Kaoru,Kurosaki Masayuki,Kaneko Shun^ORCID,Inada Kento,Yamashita Koji,Osawa Leona,Hayakawa Yuka,Sekiguchi Shuhei,Okada Mao,Wang Wan,Higuchi Mayu,Takaura Kenta,Maeyashiki Chiaki,Tamaki Nobuharu,Yasui Yutaka,Nakanishi Hiroyuki,Itakura Jun,Takahashi Yuka,Asahina Yasuhiro,Izumi Namiki^ORCID

Funder

Japan Agency for Medical Research and Development

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference23 articles.

1. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial;M Kudo;The Lancet,2018

2. Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis;A Hiraoka;Hepatology Research,2018

3. Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis;A Hiraoka;Cancer Medicine,2019

4. Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib;K Kodama;Oncology,2019

5. Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis;A Hiraoka;Hepatol Res,2019

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subsequent locoregional therapy prolongs survival in progressive hepatocellular carcinoma patients under lenvatinib treatment;Journal of the Formosan Medical Association;2024-02

2. A single-institution retrospective exploratory analysis on the effectiveness and safety of lenvatinib plus pembrolizumab for advanced endometrial cancer: insights from ProMisE molecular classification system;Japanese Journal of Clinical Oncology;2024-01-20

3. An observational, prospective, open label, multicenter study to evaluate the safety and effectiveness of pegfilgrastim as secondary prophylaxis to decrease the incidence of febrile neutropenia in Korean female patients with breast cancer;The Breast;2023-12

4. Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib;2023-10-24

5. A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study;Clinical Cancer Research;2023-10-05